zepbound eli lilly - Search News

News

Eli Lilly, Novo Nordisk

Eli Lilly: 50% Upside For LLY Stock?

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Fast Company on MSN · 1d

Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors remain unconvinced.

The Financial Times · 1d

Eli Lilly obesity pill disappoints and gives boost to arch-rival Novo Nordisk

Shares in US-based Lilly fell 14.2 per cent on the trial results, while stock in Danish arch-rival Novo Nordisk, the maker of the pioneering Ozempic weight-loss drug, rose 6.7 per cent. Novo Nordisk has been losing share to Lilly in the US in injectable weight-loss drugs.

Eli Lilly weight loss pill shows promise

CBS News on MSN · 1d

Eli Lilly weight loss pill shows promise in latest clinical trial

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.

UPI on MSN · 8h

Initial results show promise for Eli Lilly's new weight loss drug

Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount of weight, the company said.

USA TODAY · 10h

Eli Lilly closer to breakthrough weight loss drug; shares tumble as some question results

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial saw people lose 12% of body weight.

2d

Eli Lilly Q2 Preview: Can Mounjaro and Zepbound Keep Delivering?

Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

Pharmaceutical Technology on MSN1d

Mounjaro and Zepbound fuel strong Q2 growth for Eli Lilly

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...

1d

Eli Lilly second quarter earnings beat on strong GLP-1 sales, but stock dives on GLP-1 pill trial results

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

14hon MSN

Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?

The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...

Makers of Wegovy, Zepbound face competition from compounding pharmacies

The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

Medindia on MSN1d

Zepbound Approved as First Drug for Sleep Apnea in Obese Adults

Zepbound functions by targeting hormone receptors related to appetite regulation, specifically glucagon-like peptide-1 and ...

3don MSN

Evers announces $100 million tax credits deal with Eli Lilly for Kenosha County development

Eli Lilly is investing up to $4 billion in the Bristol project and Wisconsin plans to provide up to $100 million in ...

Daily Journal3d

More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

At least 26 patients have filed lawsuits in Marion County against Eli Lilly and Co. over its marketing of GLP-1 drugs ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results